Edition:
United States

People: Biocept Inc (BIOC.OQ)

BIOC.OQ on NASDAQ Stock Exchange Capital Market

0.95USD
4:00pm EDT
Change (% chg)

$-0.03 (-3.06%)
Prev Close
$0.98
Open
$0.97
Day's High
$0.97
Day's Low
$0.93
Volume
119,075
Avg. Vol
445,676
52-wk High
$12.12
52-wk Low
$0.66

Hale, David 

Mr. David F. Hale is Non-Executive Chairman of the Board of the Company. Mr. Hale was appointed as our Executive Chairman in March 2011. As of and in connection with the closing of our initial public offering on February 10, 2014, Mr. Hale now serves as non-executive Chairman. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is currently serving as Executive Chairman and Acting President and CEO of Neurana Pharmaceuticals, Inc. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences companies. He served as the Chairman of Santarus, Inc., a specialty biopharmaceutical company, since 2004 and a member of Santarus’ board since 2000, prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014. He also serves as Chairman of Conatus Pharmaceuticals, Inc, a public company. He was previously President and CEO of CancerVax Corporation from October 1999 through its merger in May 2006 with Micromet, Inc., when he became Chairman of the combined companies. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc., and as Chairman of SkinMedica, Inc., before its acquisition by Allergan, Inc. He also serves as Chairman of Adigica Health, Inc., Clarify Medical, Inc., MDRejuvena, Inc., Neurelis, Inc. and Recros Medica, Inc. In 1982, after joining Hybritech, Inc., the first monoclonal antibody company, he served as COO, President and then Chief Executive Officer, when Hybritech was acquired by Eli Lilly and Co. in 1986. From 1987 until 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was later acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995, when Viagene was acquired by Chiron, Inc. He was President and CEO of W

Basic Compensation

Total Annual Compensation, USD 111,289
Restricted Stock Awards, USD --
Long-Term Incentive Plans, USD --
All Other, USD 829,423
Fiscal Year Total, USD 940,712

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

David Hale

940,712

Michael Nall

1,139,840

Timothy Kennedy

622,437

Lyle Arnold

550,676

Edwin Hendrick

--

Michael Terry

--
As Of  30 Dec 2017